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TREATMENT OPTIONS FOR PARKINSON’S DISEASE 
Sara Russ 
INTRODUCTION 
Parkinson’s disease was first described and named Paralysis Agitans in 1817 by 
British physician James Parkinson (Lieberman 2004). Later on, it took on its current 
name after Dr. Parkinson. Parkinson’s disease (PD) is a neurological disorder for 
which the cause is yet to be discovered. Like many other diseases, PD has numerous 
facets. Throughout all of its different stages, it presents with motor, as well as non-
motor, symptoms (Simuni et al. 2009). Though estimates of people affected by PD are 
constantly being made, it is difficult to determine a precise and accurate number. This 
difficulty arises since symptoms are often mistaken for other diseases of the nervous 
system (jointly known as Parkinsonism) or are mistakenly attributed to the normal 
aging process. It is estimated that over 1 million people in North America are affected 
by this degenerative disorder. As life expectancy increases, incidence of the disease 
rises (Lang and Lozano 1998). 
The mortality rate of PD patients is 2-5 times greater than age-matched 
controls; this alone indicates the significance of its impact. It is predicted that, by the 
year 2040, Parkinson’s disease will surpass cancer as the second leading cause of death 
among the aged (Bennett et al. 1996). 
NEUROPATHOLOGY 
Parkinson’s disease is characterized by slow movement, rigidity, and 
involuntary movement, which occur because of death to dopamine-producing neurons. 
Dopamine is the main neurotransmitter to be affected by the disease, although it is not 
the only one; serotonin, acetylcholine, and norepinephrine are other affected 
neurotransmitters.  However, their contribution to clinical symptoms is unknown.  
The striatonigral complex is the region of the brain that is the source for the 
majority of the brain’s dopamine.  It includes the putamen, caudate, and substantia 
nigra; the substantia nigra is the main source of dopamine in the region. There are 5 
dopamine receptors (D1-D5) found in various brain regions that include the cortex, 
striatum, and limbic system (Macphee and Stewart 2007).  Three of the receptors (D1, 
D2, and D3) are present in the basal ganglia. D1 and D2 receptors are known to 
promote voluntary movement; D3’s function is unknown. The limbic system, which 
controls emotion, contains D3, D4, and D5 receptors; thus, the dopamine deficiency of 
PD leads to the cognitive and emotional impairments associated with PD (Rezak 
2007).  
The basal ganglia have a circuit that enables voluntary and involuntary 
movement (Macphee and Stewart 2007). Nigral cells have axons that extend into the 
putamen and caudate nucleus. The globus pallidus located near this complex regularly 
inhibits movement by releasing the neurotransmitter gamma amino butyric acid 
(GABA), an inhibitory neurotransmitter, to the thalamus, which prevents the motor 
cortex from being excited. The substantia nigra excites the caudate and putamen via 
the transmission of dopamine, which then informs the globus pallidus as to which 
forms of movement it should stop inhibiting. Thus, dopamine is necessary for motor 
output and decreased stimulation by dopamine causes decreased motor output (Kalat 
2009). 
14 Sara Russ 
The distinguishing characteristic of Parkinson’s disease was once thought to be 
the presence of Lewy bodies. However, not all forms of the disease have this 
pathological feature. For example, those that are classified as autosomal recessive cases 
do not have Lewy bodies. In autosomal dominant cases, however, Lewy bodies are 
seen (Macphee and Stewart 2007). Lewy bodies are spherically shaped protein masses 
and contain transparent cytoplasmic centers with halos surrounding them. The center 
consists of neurofilaments and other proteins accountable for proteolysis (protein 
breakdown) including parkin, ubiquitin, and alpha synuclein. In those patients who 
experience Lewy bodies, Lewy bodies appear in all affected areas of the brain (Dauer 
and Przedborski 2003). The mechanism of formation of Lewy bodies and their 
function in the pathology of the disease is not yet known (Lang and Lozano 1998). 
Many areas of the brain are affected by the disease. The most significant 
damage occurs in the pars compacta, the posterior part of the substantia nigra 
(Macphee and Stewart 2007). This region is located in the midbrain, midway between 
the cerebral cortex and the spinal cord (Lieberman 2004). Most of the motor 
symptoms associated with the disease occur because of damage to this area. Motor 
symptoms begin to appear after the majority of the cells in this area are lost. Damage 
to the nucleus basalis, an area of the brain that produces an abundance of the 
neurotransmitter acetylcholine, is correlated with impaired memory and cognitive 
function in PD patients (Macphee and Stewart 2007). 
The pars compacta has both anterior and posterior parts to it. The posterior 
part is pigmented with neuromelanin, whereas the anterior is considerably lighter, as it 
lacks this pigment. Normal aging is consistent with cell loss in the posterior region. 
PD, on the other hand, impairs the anterior region. This shows that Parkinson’s 
disease is not an effect of advanced aging (Macphee and Stewart 2007). 
Studies show that neurological symptoms of Parkinson’s disease develop in an 
upward manner. The disease starts with damage to the brainstem and advances 
upward to the cerebral cortex. The disease can be divided into six stages, each 
associated with the onset of specific neurological symptoms (Macphee and Stewart 
2007). In the first two stages, symptoms are not apparent (Davie 2008). 
CAUSES 
GENETIC CAUSES 
Most incidences of PD occur sporadically, rather than from genetic causes 
(Wood-Kaczmar et al. 2006). Onset generally occurs at younger ages in genetic forms 
of the disease and pathological symptoms are different (Vila and Przedborski 2004). 
Genetic inheritance of PD occurs in both autosomal dominant and autosomal recessive 
forms (Wood-Kaczmar et al. 2006). Dominantly inherited Parkinson’s was first 
discovered in the 1990s upon studying a familial case. Alpha-synuclein was the gene 
identified as causing PD (Cordato and Chan 2004). Several other genes involved in 
the onset of the disease have been located since that initial discovery (Vila and 
Przedborski 2004). 
ALPHA SYNUCLEIN 
A mutated SNCA gene, which encodes the alpha synuclein protein, has an 
altered sequence of nucleotides (Vila and Przedborski 2004) and therefore codes for a 
different protein product (Klug et al. 2006). Three types of mutations were found that 
link this gene to Parkinson’s disease. These genetic mutations are only associated with 
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dominant inheritance (Wood-Kaczmar et al. 2006).  Mutations in SNCA are thought to 
account for a small percentage of Parkinson’s disease since it was found in a small 
number of studied hereditary cases (Lang, and Lozano 1998). 
Alpha synuclein is made up of 140 amino acids and is present in several 
locations of the brain. It is found in the highest concentrations in the cortex, 
hippocampus (Wood-Kaczmar et al. 2006), hypothalamus, olfactory neurons, and 
substantia nigra. Neural and glial cells produce this protein, which is mainly found at 
pre-synapses. Alpha synuclein has the shape of an alpha helix and is found in vesicles 
that transport lipids.  
Studies were done on mice by transferring a gene from another organism to 
replace the gene that encodes for alpha synuclein, in order to test its function in living 
organisms. Absence of alpha synuclein showed fewer proteins at synapses and fewer 
vesicles available for transport (Cordato and Chan 2004). Its function is not well 
understood, although it is thought to play a role in transmission of chemical messages, 
learning, and neuroplasticity (the ability for neurons to adapt to environmental stimuli) 
(Wood-Kaczmar et al. 2006).  
Alpha synuclein can also be harmful.  In high concentrations, these proteins 
cluster together to form polypeptides that are associated with various diseases. These 
unwanted protein accumulations are normally broken down by enzymes that specialize 
in getting rid of harmful material to the cell. Toxicity to neurons can happen if mutated 
SNCA produces alpha synuclein proteins that are more likely to clump together or are 
folded in such a way that makes it difficult for enzymes to break them down. These 
proteins are part of Lewy body formation and are thought to cause cell death by 
breaking down the proteins of neurons (Cordato and Chan 2004).  
LEUCINE-RICH REPEAT KINASE 2 
A number of mutations in the gene that encodes for leucine-rich repeat kinase 2 
(LLRK2) have been located in late-onset dominantly inherited PD. The most common 
one is substitution of the G2019S gene. This mutation generally accounts for a small 
percentage of genetically inherited PD. It contributes to a significantly greater 
percentage of PD in North African Arabs and Ashkenazic Jews. The role of this 
protein and its contribution to the disease is not yet understood (Wood-Kaczmar et al. 
2006).  
PARKIN 
Parkin is made up of 465 amino acids. It is one of many proteins that have a 
ring finger domain. Proteins that have this characteristic are able to act as ubiquitin 
ligases by breaking down harmful protein buildup, such as buildup of alpha synuclein. 
Mutations in the gene that encodes for parkin, PARK2, are due to recessive inheritance 
and are consistent with early-onset PD (Cordato and Chan 2004). Mutations of 
PARK2 and alterations in parkin’s post-translational state cause parkin’s inability to 
target certain forms of alpha synuclein for breakdown, which can lead to build-up of 
alpha synuclein and toxicity to neurons (Vila and Przedborski 2004). In addition, 
mutations in other proteins do not permit parkin to carry out its job properly, resulting 
in toxic accumulation (Wood-Kaczmar et al. 2006).  PARK2 mutations cause death to 
cells of the substantia nigra and locus ceruleus (Cordato and Chan 2004).  
Parkin functions as an ubiquitin enzyme marking its target cell for destruction. 
Lewy bodies form when a sequence of ubiquitin enzymes binds to a target protein and 
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is unable to break it down. In its mutated forms, parkin cannot bind to its target 
proteins; thus, Lewy bodies are not seen in this instance (Cordato and Chan 2004).   
The two types of mutations (Wood-Kaczmar et al. 2006) in the PARK2 gene 
(missense and nonsense mutations) cause very similar symptoms, such as early onset 
(usually occurring before age 30) (Cordato and Chan 2004; Vila and Przedborski 
2004), degeneration at a slower pace, receptiveness to levodopa (a medication used to 
treat motor symptoms of PD) (Macphee and Stewart 2007), and susceptibility to side 
effects of levodopa early on (Cordato and Chan 2004). Mutations in the PARK2 gene 
account for 50 percent of early-onset familial PD and for 77 percent of early-onset 
sporadic cases (Wood-Kaczmar et al. 2006). 
PARK7  
The gene PARK7 codes for DJ-1, a protein with many functions. It is found 
scattered in many areas of the brain. Several recessive mutations link this protein to 
PD. Compared to mutations in PARK2, mutations in DJ-1 account for a small amount 
of early onset PD. Mutations occur in various areas of the gene, yet they cause the 
same symptoms (Vila and Przedborski 2004). The normal function of DJ-1 is to 
stabilize proteins, while protecting them from damage by free radicals. Studies on mice 
that lack DJ-1 have shown dysfunction of dopamine pathways, causing motor 
disability (Wood-Kaczmar et al. 2006).  
ENVIRONMENTAL CAUSES 
The development of PD in a group of drug users was linked to the intake of a 
drug containing methyl-phenyl-tetrahydropyridine (MPTP). MPTP has been shown 
to cause degeneration specifically in the nigral cells, by decreasing complex 1 (the first 
enzyme of the respiratory chain leading to the production of ATP) activity of the 
mitochondria. The discovery that environmental toxins can lead to the onset of PD has 
led researchers to extend their studies to pesticides and herbicides to test their 
contribution to the disease (de Lau and Breteler 2006). Rotenone is an agent 
commonly used by gardeners to prevent unwanted plant growth. Repeated exposure to 
this chemical in low doses has also been shown to cause degeneration specific to nigral 
cells. Studies show that exposure to this pesticide is linked to the formation of Lewy 
bodies, a major component of the PD, whereas exposure to MPTP has not yielded 
such results (Jenner 2001). It has been hypothesized that exposure and accumulation 
of heavy metals, such as aluminum, amalgam, copper, iron, manganese, zinc, etc., in 
the substantia nigra may cause an increased risk of PD by causing oxidative damage 
(de Lau and Breteler 2006).  
SYMPTOMS 
MOTOR SYMPTOMS 
A number of motor features, including bradykinesia (slow movement), a resting 
tremor, muscle rigidity, and postural instability, distinguish PD from Parkinsonism. 
There are several scales to assess the rate of decline in PD patients. Two widely used 
scales are the Hoehn and Yahr, and the Unified Parkinson’s disease rating scale 
(UPDRS). The Hoehn and Yahr, a scale that ranges from 0 (no symptoms) to 5 
(bedridden) evaluates how far the disease has progressed. The UPDRS, on the other 
hand, is used to determine speed of progression of the disease. This scale is currently 
being modified to include non-motor symptoms of PD (Jankovic 2007). 
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The most apparent symptom of the disease is bradykinesia, or decreased 
movement. Bradykinesia adds difficulty to daily activity management, leading to an 
inability to initiate, plan, multitask, and/or carry out tasks in a consecutive order. Slow 
movement affects fine motor function such as buttoning a garment and handling 
utensils. Spontaneous movement, such as blinking, facial expressions, and arm 
swaying while walking, is also impaired. These hindrances are due to reduced 
dopamine activity, which causes a decrease in motor output (Jankovic 2007).  
Slowness of movement is related to the patient’s emotional state, not their motor 
abilities.  Thus, when an external stimulus, such as a yell of “Fire” or a signal telling 
them to beware of an obstacle, informs them of the need for quick movement, they 
regain the ability to move quickly (Jankovic 2007). 
According to studies (Gelb et al. 1999), the most common symptom of PD 
(Jankovic 2007), which occurs in 79-90 percent of patients, is a resting tremor. Hand 
tremors begin on one side of the body and spread to the other. It is noticeable on the 
lateral parts of the hand or leg. Tremors may also affect the chin, jaw, lips, and legs. 
Tremors are not apparent while sleeping or in the course of action (Jankovic 2007).  
Another feature seen in PD is stiffness, which can occur in several areas, such 
as the ankles, hips, neck, shoulders, and wrist. Stiffness can be accompanied by pain. A 
study found that rigidity, along with tremor and imbalance, was associated with an 
increased risk of PD in individuals who initially showed no signs of Parkinsonism 
(Jankovic 2007). 
 Rigidity can also cause bending of the elbows, knees, neck, and/or trunk. It can 
also lead to striatal hand or foot, which occurs when the thumb or big toe is extended 
while the joint by the knuckles and other toes are bent. These abnormalities usually 
occur later on in the disease and are generally associated with early onset of the disease 
(Jankovic 2007).  
Postural instability usually arises in later stages of the disease. This symptom is 
the source for many falls that often cause hip fractures. One study indicated a wait of 
nine years for patients to experience their first fall. Interestingly, patients who fear 
falling show an increased incidence of falling. Unlike other symptoms, postural 
imbalance is generally untreatable by therapy (Jankovic 2007).  
NON-MOTOR SYMPTOMS 
Non-motor aspects of PD are currently receiving increased attention, since 
they affect the quality of life of patients significantly (Macphee and Stewart 2007). 
Non-motor features consist of autonomic dysfunction, sleep disorders, and impaired 
cognitive function (Jankovic 2007).  
Autonomic dysfunction includes sweating, constipation, erectile dysfunction, 
orthostatic hypotension (a sudden decrease in blood pressure when the patient stands 
up) (Jankovic 2007), and reduced olfaction (Chaudhuri et al. 2006). Constipation is a 
common symptom that can serve as a precursor to PD. A study done over a period of 
24 years showed that men who originally had constipation were three times more likely 
to develop PD, following a 10 year interval. Both elevated and decreased sex drive 
were reported by patients.  Ninety percent of PD patients develop problems with their 
sense of smell. A number of studies concluded that decreased sense of smell is an early 
sign of motor symptoms in PD. Many relatives of patients who reported reduced 
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olfaction but did not report any other symptoms of PD were later diagnosed with PD 
(Chaudhuri et al. 2006).  
Sleep disruption was once thought to be a side effect of treatment for 
Parkinson’s. Several doctors now believe that it is a component of the disease. About 
one third of PD patients have rapid eye movement sleep behavior disorder where a 
dream accompanies dramatic motor movement. Insomnia occurs in over 50 percent of 
patients (Jankovic 2007). Sleepiness during daytime hours is common and may result 
from sleep disruption at night or as an outcome of treatment (Macphee and Stewart 
2007).  Degeneration of neurons in the brain’s sleep regulation centers in the 
thalamocortical pathway and brainstem contribute to sleep disorders (Chaudhuri et al. 
2006).  
Studies have found decreased cognitive ability in nearly 85 percent of PD 
patients, while close to half of them developed dementia. Dementia in PD patients 
usually accompanies neuropsychiatric disorders. A study comprising 537 PD patients 
showed that close to 50 percent experienced anxiety, apathy, depression, and 
hallucinations. Other studies reveal that many patients display various forms of 
impulsive behavior, such as cravings, hypersexuality, obsession with shopping, 
pathological gambling, etc. These behaviors develop as a result of taking levodopa 
(Jankovic 2007), a medication used to treat PD (Macphee and Stewart 2007).  
PREVENTION 
Several case-control and population-based studies from numerous countries 
showed a significantly decreased risk for PD among cigarette smokers. The 
mechanism of cigarette smoking decreasing the risk of PD is not well understood. It is 
possible that nicotine in cigarettes stimulates dopamine release.  
Several studies also found consumption of coffee to be consistent with a 
reduced risk for PD. The effective component in coffee is perhaps caffeine, because 
other studies showed a decreased risk for PD from taking in other sources of caffeine. 
According to studies, caffeine has a greater protective effect on men than woman (de 
Lau and Breteler 2006).  
A third factor that may reduce risk of PD is alcohol consumption.  Some 
studies found a decreased risk with alcohol consumption.  Others, though, found no 
association (de Lau and Breteler 2006). 
DIAGNOSIS 
The main symptoms of PD at the time of diagnosis include rigidity, 
bradykinesia, and a resting tremor (Davie 2008). Postural instability is usually not 
present during diagnosis since it typically manifests itself later on in the disease 
(Jankovic 2007). Symptomatic features are generally not present on both sides of the 
body. Handwriting change and decreased facial expressions can be detected. 
Decreased olfaction can be reported since it is usually an early symptom of PD. Post-
mortem studies showed that diagnosis of PD by a neurologist reflected a 25 percent 
misdiagnosis rate. Patients who were diagnosed in a clinic that specialized in 
movement disorders indicated less diagnostic inaccuracy. It is thus important to see an 
expert in the field to ensure proper diagnosis (Davie 2008).  
There are several Parkinsonism disorders that can easily be mixed up with PD.  
Diagnosis of PD normally takes place in a clinical setting. Sometimes brain images 
using magnetic resonance imaging (MRI) and computed tomography (CT) are 
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necessary to rule out other Parkinsonism diseases.  Using single emission 
computerized tomography (SPECT), other conditions can be ruled out (Davie 2008).  
TREATMENT OF MOTOR SYMPTOMS 
LEVODOPA 
Each patient requires treatment dedicated to his or her specific symptoms and 
needs (Rezak 2007). Since the 1960s, levodopa has been the main drug used in 
treatment of PD (Schapira et al. 2006). Levodopa greatly reduces symptoms of rigidity 
and bradykinesia, but has a lesser effect on tremors (Macphee and Stewart 2007). 
Levodopa is currently the most effective drug on the market. However, since 
levodopa’s effectiveness lasts for about ten years (Rezak 2007), it is held back from 
patients or given at low doses until it is absolutely necessary.  
In order to reduce its side effects, levodopa may be combined with other drugs.  
Levodopa, a dopamine precursor, is usually combined with a decarboxylase inhibitor 
(Macphee and Stewart 2007), such as carbidopa or benserazide. These inhibitors 
occupy receptors on the enzyme dopa decarboxylase, thus preventing levodopa’s 
conversion to dopamine before it reaches the brain. Decarboxylase inhibitors help 
alleviate side effects that accompany levodopa such as excessive sweating, low blood 
pressure, and nausea. Another drug that may be combined with levodopa and 
carbidopa is entacapone. This drug inhibits catechol-o-methyl-transferase, an enzyme 
that breaks down neurotransmitters, causing increased uptake of levodopa in the 
intestines.  
Even when combined with other drugs, there are possible side effects that 
accompany levodopa (Rezak 2007). After five years of taking levodopa, 50 percent of 
patients may develop (Lieberman 2004) dyskinesia, motor fluctuations, hallucinations, 
sleepiness, nausea, and/or low blood pressure (Rao et al. 2006). Levodopa induced 
motor fluctuations can range between wearing off of dosage and unsystematic severe 
on and off motor functioning. Levodopa’s half-life of 60-90 minutes causes a spurt of 
dopamine receptor activation. The occurrence of continuous abrupt spurts of 
dopamine receptor activation at the same time as the constant death of dopamine-
producing cells causes abnormal receptor activation known as the “on-off” 
phenomenon. Initially, levodopa is prescribed very sparingly in order to protect 
patients from its adverse side effects (Rezak 2007). 
DOPAMINE AGONISTS 
Dopamine agonists activate dopamine receptors by mimicking the actions of 
dopamine (Lieberman 2004). They include bromocriptine, cabergoline, lisuride, 
pergolide, pramipexole, ropinerole, and rotigotine (Macphee and Stewart 2007). 
Dopamine agonists, which have been previously prescribed together with levodopa, 
are currently being given alone as an early PD treatment, thereby delaying the 
administration of levodopa. Pramipexole, ropinerole (Rezak 2007), and rotigotine are 
currently the most prescribed dopamine agonists (Davie 2008). Studies comparing the 
effects of pramipexole and ropinerole against levodopa have shown a decreased rate of 
progression of PD with levodopa use. The dopamine agonists, however, showed less 
motor complications (Rao et al. 2006). With advancement of the disease, dopamine 
receptor agonists are commonly taken with levodopa/carbidopa to reduce levodopa’s 
accompanied motor complications (Lieberman 2004). Possible side effects of 
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pramipexole and ropinerole can include low blood pressure, dyskinesia, abnormal 
sleep patterns, impulsive behavior, and cognitive/psychiatric impairments. Unlike the 
other dopamine agonists, rotigotine is administered through a transdermal patch and is 
absorbed over a 24-hour period, thereby continuously stimulating dopamine receptors. 
Pergolide, bromocriptine (Rezak 2007), cabergoline, and lisuride are not prescribed 
that often since they cause cardiac valve degeneration (Davie 2008). 
MONOAMINE OXIDASE-B INHIBITORS (MAO-B) 
The enzyme monoamine oxidase-B (MAO-B) is responsible for degrading most 
of the dopamine in the basal ganglia. Selegiline and rasagiline are two drugs that 
inhibit this enzyme causing increased levels of available dopamine (Rezak 2007). Like 
dopamine agonists, selegiline can either be used alone to treat symptoms while 
delaying levodopa therapy or be joined with levodopa to reduce motor fluctuations 
(Macphee and Stewart 2007). Insomnia and nausea are potential side effects of this 
drug (Rao et al. 2006). Rasagiline is a newer and more powerful MAO-B inhibitor 
than selegiline. Rasagiline is an effective monotherapy in early PD as well as a 
preventer of motor fluctuations when taken with levodopa later on in the disease’s 
progression (Rezak 2007). Compared to a placebo, when taken with levodopa, 
rasagiline has shown to decrease motor fluctuations by one more hour per day 
(Macphee and Stewart 2007).   
CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT-I) 
Catechol-O-methyltransferase is an enzyme present in several locations, 
including the intestines, liver, kidneys, neural cells and glial cells. The goal of 
tolcapone and entacapone, the two catechol-O-methyltransferase inhibitors (COMT-
I), is to prevent motor fluctuations resulting from the wearing off of levodopa's effects 
between doses (Macphee and Stewart 2007). These drugs can improve symptoms and 
effectively reduce the dose of levodopa (Rao et al. 2006). COMT-I drugs inhibit 
metabolism of levodopa by COMT in the gastrointestinal tract, thus increasing the 
amount of levodopa reaching the substantia nigra and thereby enabling levodopa’s 
conversion to dopamine. In addition to increasing the availability of levodopa to the 
brain, tolcapone and entacapone also prolong the duration of levodopa's metabolism. 
COMT inhibitors can be good treatments for early Parkinson's disease. They delay the 
onset of levodopa's motor complications by stabilizing the blood concentration of 
levodopa and effectively decreasing peak dosage, via the increase of levodopa's half-life 
(Rezak 2007).  
COMT-I drugs can have negative effects as well.  Diarrhea can occur as a side 
effect (Rao et al. 2006), necessitating discontinuation of the drug. The addition of 
COMT inhibitors to levodopa therapy causes increased dopaminergic stimulation, 
possibly resulting in dyskinesia. Such cases may call for decreased dosage. Since 
tolcapone has been shown to cause hepatotoxicity, the FDA requires patients' liver 
enzymes to be monitored (Rezak 2007); it is thus given only when entacapone proves 
to be ineffective (Macphee and Stewart 2007). Although it has a shorter half-life and is 
less effective, entacapone is still more frequently used (Rezak 2007).  
AMANTADINE 
 Amantadine, initially an antiviral drug, was discovered to be useful in 
PD treatment (Lieberman 2004) by improving dopamine release from presynaptic 
 Treatment Options for Parkinson’s Disease 21 
 
terminals (Rezak 2007) and acting as an anticholinergic agent, which prevents 
glutamate activation of N-methyl-D-aspartate (NMDA) receptors (Lieberman 2004). 
Overstimulation of NMDA receptors are linked to dopaminergic death in PD. 
Amantadine’s impact on treating symptoms is greatest for tremor and it has its greatest 
effects in the early PD stages. It has also shown to reduce dyskinesia associated with 
levodopa (Rezak 2007). Side effects of this drug may include hallucinations, confusion, 
hypotension, nausea, and edema (Rao et al. 2006).  
Source: Cordato and Chan 2004 
Table 1: FDA Approved Medications for Parkinson’s Disease 
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ANTICHOLINERGICS 
Anticholinergic drugs also treat tremor in PD. Trihexyphenidyl, benztropine, 
and procyclidine, are the most commonly used anticholinergic drugs. Due to their 
adverse effects, they should not be given to the elderly. Side effects of anticholinergic 
drugs can include blurred vision (Rezak 2007), dry mouth, hypotension, constipation 
and cognitive impairment (Rao et al. 2006). 
SURGERY 
Brain surgery used to be a common method for treating tremor and rigidity in 
Parkinson patients, although success rates varied and detrimental risk factors such as 
death were involved. However, with the advent of levodopa in the 1960s, which 
proved to be a safer and more effective option for treatment, the idea of surgery 
diminished. With advances in neuroimaging, surgery has regained popularity as a 
treatment for PD among those who do not respond to drug therapy anymore 
(Lieberman 2004). 
With greater understanding of the neuropathology involved in PD, two 
ablative procedures are renewably performed (Arle and Alterman 1999) to help 
control symptoms of PD (Lieberman 2004). A thalamotomy involves destroying part 
of the ventrolateral thalamus, a brain region involved in transmitting signals that 
control movement. This procedure significantly reduces tremor but shows little 
improvement to symptoms of rigidity and bradykinesia. Death rates are less than 1 
percent due to better targeting and lesion technique. Since thalamotomy does not 
significantly improve many symptoms of PD, it is less favored than pallidotomy (Arle 
and Alterman 1999). 
In a pallidotomy, the globus pallidus, a brain area responsible for involuntary 
intermittent movements in PD patients, is targeted (Lieberman 2004).  Pallidotomy 
has been shown to greatly reduce rigidity, bradykinesia, and tremor. Patients taking 
levodopa can also benefit from this procedure because it decreases the "off" period in 
their motor fluctuations. Better UPDRS scores were reported for up to 2 years 
following this procedure (Arle and Alterman 1999). 
Deep brain stimulation has become more common now because of its 
effectiveness. The head of the patient is placed in a stereotaxic frame, a halo-like 
device. Surgeons can spot the thalamus, globus pallidus, or the subthalamic nucleus 
through MRI on the brain. The skull is pierced, using a drill, and a probe is placed 
deep inside the brain to reach the target tissue. The probe transmits a burst of 
electricity, which causes the brain region’s electrical activity to normalize reversing PD 
symptoms. This is a safe surgery and results can be seen immediately (Lieberman 
2004).  
STEM CELL THERAPY 
Currently there is no cure for PD. Embryonic stem cells and stem cells that 
come from fetal brains and adult bone marrow have been successfully transformed into 
functioning dopamine producing cells. However, there are several setbacks. Use of 
embryonic stem cells is controversial (Arias-Carrion and Yuan 2009) as many people 
believe that fetal tissue should not be used for research as a fetus is unable to consent 
(McLaren 2001). Many believe that adult stem cells have much to offer for future 
treatment of degenerative diseases such as PD. Previously, adult stem cells have been 
scarce, but recent progress enables their use in large quantities. Adult stem cells can be 
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implanted into the brain where it can differentiate into neural cells. With a better 
understanding of the immune system and successful transplantation, the use of stem 
cells is under serious consideration for treating the various dimensions of PD. It is 
hypothesized that stem cells should come from the very same patient who will derive 
benefit from it; however, not much is known about this type of implantation. The 
current goal under study is to test the use of autologous stem cell transplant in animals, 
and further the findings to clinical studies (Arias-Carrion and Yuan 2009). 
CONCLUSION 
Parkinson's disease is a multi-dimensional disease for which there is currently 
no cure. Much advancement has been made in the treatment of PD symptoms as 
opposed to curing it. Current research is giving increased attention to treatment of 
non-motor symptoms since it greatly affects the quality of life of patients. Additionally, 
increasing focus is being given to stem cell research as a potential cure for Parkinson’s 
disease by using the patient’s own stem cells to repair their damaged dopaminergic 
tissue. 
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